Anti-Bevacizumab ELISA Kit (DEIABL202)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
Serum, plasma
Species Reactivity
Human
Intended Use
Qualitative Antibodies to Bevacizumab ELISA has been especially developed for the qualitative analysis of antibodies to bevacizumab in serum and plasma samples.
Storage
The kit is shipped at ambient temperature (10-30°C) and should be stored at 2-8°C for long term storage. Keep away from heat or direct sunlight. The strips of microtiter plate are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.
Precision
Intra-assay and inter-assay CVs <30%.
General Description
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab is an antineoplastic agent and prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metastatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation.

Citations


Have you cited DEIABL202 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Tang, PA; Moore, MJ; et al. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 6:459-473(2013).
Cabanas, R; Saurez, G; et al. Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 29:173-178(2014).

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket